The beleaguered Myriad Genetics, besides facing ongoing legal battles over BRCA gene patents in the US (see previous news), now faces challenge in the Australian courts.
 
The Federal Court is hearing a case against Myriad and their exclusive Australian licence holder for BRCA1 mutation testing, Genetic Technologies, brought by the organisation Cancer Voices Australia in partnership with a cancer survivor, Yvonne D'Arcy.
 
They say that the BRCA1 patent is invalid on the grounds that it is a discovery as opposed to an invention; Myriad is contesting the suit.

Meanwhile, the Melbourne-based Genetic Technologies has taken steps towards launching their own breast cancer risk assessment test in the US; the test, which assays a selection of genetic variants, has received laboratory approval from the US Centers for Medicare and Medicaid Services. 

comments powered by Disqus